- Record: found
- Abstract: found
- Article: not found
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
Pierre Fenaux
1 ,
Ghulam J Mufti ,
Eva Hellström-Lindberg ,
Valeria Santini ,
Norbert Gattermann ,
Ulrich Germing ,
Guillermo Sanz ,
Alan F List ,
Steven Gore ,
John F Seymour ,
Hervé Dombret ,
Jay Backstrom ,
Linda Zimmerman ,
David McKenzie ,
C L Beach ,
Lewis R Silverman
Feb 01 2010
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
In a phase III randomized trial, azacitidine significantly prolonged overall survival (OS) compared with conventional care regimens (CCRs) in patients with intermediate-2- and high-risk myelodysplastic syndromes. Approximately one third of these patients were classified as having acute myeloid leukemia (AML) under current WHO criteria. This analysis compared the effects of azacitidine versus CCR on OS in this subgroup.